Drug Approval | July 10, 2024
Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Subscribe To Our Newsletter & Stay Updated
